Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ID Biomedical StreptAvax

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Group A streptococcus vaccine was reported to be safe and well tolerated in 10 adult volunteers at a 50 mcg dose, and "all subjects developed antibody responses to the vaccine," the company said. The trial will continue with ten volunteers tested at each of three doses: 50, 100, and 200 mcg. The study is sponsored and funded by the National Institute of Allergy and Infectious Diseases. The company describes the injectable vaccine as "made from the terminal fragments of the surface M protein," and "designed to produce a preventative immune response against six different strains of group A streptococcus.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001054

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel